Brief: Brainstorm Cell Therapeutics Inc Says On July 18, Co Received MVLS Deficiency Notice From The Listing Qualifications Department Staff Of Nasdaq
19/07/2024 21:24
July 19 (Reuters) - Brainstorm Cell Therapeutics Inc
BCLI.O :
* BRAINSTORM CELL THERAPEUTICS INC SAYS ON JULY 18, CO
RECEIVED
MVLS DEFICIENCY NOTICE FROM THE LISTING QUALIFICATIONS
DEPARTMENT STAFF OF NASDAQ
Source text for Eikon: ID:n0001104659-24-081162
Further company coverage: BCLI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Brainstorm Cell Therapeutics
See all newsBrief: Brainstorm Appoints Former FDA Associate Commissioner Peter J. Pitts As Executive Chairman
Brief: Brainstorm Cell Therapeutics Announces First Quarter 2026 Financial Results And Provides Corporate Update
Brief: Brainstorm Cell Therapeutics Announces $1 Million Strategic Financing At Premium To Market
Brief: Brainstorm Cell Therapeutics Announces Second Quarter Financial Results
Brainstorm Cell Therapeutics Inc expected to post a loss of 37 cents a share - Earnings Preview